We adopted highly purified EPA ethyl ester, which was approved by Japan’s Ministry of Health, Labour and Welfare for the treatment of peripheral artery disease and hyperlipidemia, to examine its effects on postprandial glucose and insulin metabolism [11, 12]. This evidence concerns the gene INS and hyperlipidemia.